Xconomy | Boston - Business + Technology in the Exponential Economy

Biotech, FDA, clinicals

Cancer Patient Can Use Newton Firm’s Drug, FDA Says

Rebecca Zacks 3/24/08

Pro-Pharmaceuticals of Newton, MA, announced today that it got the go-ahead from the FDA to treat one breast cancer patient with its lead drug candidate, Davanat. The drug, a carbohydrate polymer currently in Phase II trials for colorectal and biliary cancers, is designed to be used in combination with other cancer treatments.


Add Your Thoughts



You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted. By clicking "Publish," you are agreeing to these Terms and Conditions.

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2008 Xconomy. All rights reserved. Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.